作者
Wan-Hsuan Hsu, Bo-Wen Shiau, Ting-Hui Liu, Jheng-Yan Wu, Ya-Wen Tsai, Po-Yu Huang, Min-Hsiang Chuang, Chih-Cheng Lai, Chi-Hsing Chen
发表日期
2023/10/3
来源
Expert Review of Anti-infective Therapy
卷号
21
期号
10
页码范围
1143-1151
出版商
Taylor & Francis
简介
Objectives
This retrospective cohort study assessed the clinical effectiveness of nirmatrelvirplus ritonavir (NMV-r) in treating COVID-19 in patients with liver cirrhosis(LC).
Methods
The data of non-hospitalized adult patients with LC who had COVID-19 were selected from the TriNetX platform for the period between 1 March 20201 March 2020, and 31 December 202231 December 2022. Propensity score matching was used to match patients receiving NMV-r (theNMV-r group) with those not receiving NMV-r (the control group). Hazard ratios(HRs) along with 95% confidence intervals (CIs) for the primary outcome – a composite of all-cause hospitalization or mortality during the 30-day follow-up period – were calculated and compared.
Results
Two cohorts of 2,369 patients each with balanced baseline characteristics were identified.During the follow-up period, the NMV-r group had a lower risk of all-cause hospitalization …
学术搜索中的文章
WH Hsu, BW Shiau, TH Liu, JY Wu, YW Tsai… - Expert Review of Anti-infective Therapy, 2023